ULODESINE HEMI-GLUTAMATE

Investigational

Details

Stereochemistry	EPIMERIC
Molecular Formula	C24H30N8O5.C5H9NO4
Molecular Weight	657.6749
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 5
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

N[C@@H](CCC(O)=O)C(O)=O.OC[C@H]1CN(CC2=CNC3=C2N=CNC3=O)CC1O[C@H]4CN(CC5=CNC6=C5N=CNC6=O)C[C@@H]4CO

InChI

InChIKey=QGTAIFAWRXBESU-MECDXXGSSA-N

InChI=1S/C24H30N8O5.C5H9NO4/c33-8-15-5-31(3-13-1-25-20-18(13)27-11-29-22(20)35)7-17(15)24(37)10-32(6-16(24)9-34)4-14-2-26-21-19(14)28-12-30-23(21)36;6-3(5(9)10)1-2-4(7)8/h1-2,11-12,15-17,25-26,33-34,37H,3-10H2,(H,27,29,35)(H,28,30,36);3H,1-2,6H2,(H,7,8)(H,9,10)/t15-,16-,17?,24?;3-/m10/s1

HIDE SMILES / InChI

Molecular Formula	C24H30N8O5
Molecular Weight	510.5456
Charge	0
Count

Stereochemistry	EPIMERIC
Additional Stereochemistry
Defined Stereocenters	3 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	C24H30N8O5
Molecular Weight	510.5456
Charge	0
Count

Stereochemistry	MIXED
Additional Stereochemistry
Defined Stereocenters	2 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	C5H9NO4
Molecular Weight	147.1293
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	C5H9NO4
Molecular Weight	147.1293
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26073200 | https://adisinsight.springer.com/drugs/800020705

Ulodesine (BCX4208) is a new, orally active, highly potent inhibitor of purine nucleoside phosphorylase (PNP) for the treatment of hyperuricemia and gout. Inhibition of PNP reduces the substrates available for XO to form uric acid. The drug is currently under development for the management of hyperuricemia in chronic gout. Two Phase II clinical trials have shown promising results regarding urate-lowering effect in both as monotherapy and in combination with allopurinol. Ulodesine shows no interaction with CYP450 isoforms and has no hepatic metabolism; therefore, no drug interactions were expected. Following the successful outcome of the Phase IIb clinical trial, Phase III development of ulodesine is planned. One concern regarding the use of ulodesine is its impact on T cells. Lack of PNP is associated with immunodeficiency and autoimmune disorders.

Originator

Approval Year

PubMed

Title	Date	PubMed
Expert opinion on emerging urate-lowering therapies.	2018-09	30244605
New medications in development for the treatment of hyperuricemia of gout.	2015-03	25603039
Investigational drugs for hyperuricemia.	2015	26073200

Patents

Sample Use Guides

In Vivo Use Guide

In the 12-week randomized controlled trial, in 82 gout patients, the response rates to 5, 10, 20 and 40 mg ulodesine (BCX4208) compared with allopurinol 300 mg were 45, 33, 39 and 49%, respectively

Route of Administration: Oral

In Vitro Use Guide

Ulodesine is a novel and potent inhibitor of purine nucleoside phosphorylase (PNP) with an IC50 of 0.5 nM.

Substance Class	Chemical Created by `admin` on `Wed Apr 02 21:20:58 GMT 2025` Edited by `admin` on `Wed Apr 02 21:20:58 GMT 2025`
Record UNII	WSH2FH5UJL
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ULODESINE HEMI-GLUTAMATE

Common Name

English

Hemi L-glutamate salt of 7-[(3R,4R)-3-Hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl]-3,5- dihydro-pyrrolo [3,2-d] pyrimidin-4-one

Preferred Name

English

Code System Code Type Description

FDA UNII

WSH2FH5UJL

Created by admin on Wed Apr 02 21:20:58 GMT 2025 , Edited by admin on Wed Apr 02 21:20:58 GMT 2025

PRIMARY

Related Record Type Details


					JNG8L9460Y

ULODESINE

PARENT -> SALT/SOLVATE

Amount: